Cutaneous hypersensitivity reactions to immune checkpoint inhibitors Editorial
| Authors: | Storgard, R.; Markova, A. |
| Title: | Cutaneous hypersensitivity reactions to immune checkpoint inhibitors |
| Abstract: | The introduction of immune checkpoint inhibitors (ICIs) has transformed the management of various malignancies. Alongside their therapeutic success, the widespread application of ICIs has unveiled a spectrum of immune-related adverse events (irAEs), most often affecting the skin. Cutaneous irAEs (cirAEs) encompass a range from common morbilliform and lichenoid rashes to more severe conditions such as bullous dermatoses and psoriasiform eruptions, each presenting distinct clinical challenges. Moreover, less common but clinically severe cutaneous reactions like toxic epidermal necrolysis have also been observed. cirAEs are frequently observed, with an incidence ranging from 37% to 70% for anti–cytotoxic T lymphocyte–associated antigen-4 antibodies and 17% to 40% for anti- programmed death-1/anti–programmed death ligand-1 antibodies. Recognizing the critical need for effective therapeutic strategies, this review carefully examines current approaches and guidelines for managing cirAEs. © 2024 American Academy of Allergy, Asthma & Immunology |
| Keywords: | prednisone; rituximab; neoplasm; neoplasms; gene; drug eruption; gene expression; skin biopsy; skin defect; steroid; pathology; cancer therapy; psoriasis; pruritus; skin; immunology; gamma interferon; vitamin d; interleukin 6; methylprednisolone; interleukin 17; corticosteroid; cytotoxic t lymphocyte antigen 4; doxycycline; tacrolimus; ultraviolet b radiation; cyclosporine; interleukin 22; naloxone; tumor necrosis factor; drug eruptions; stevens johnson syndrome; toxic epidermal necrolysis; measles like rash; gabapentin; programmed death 1 ligand 1; programmed death 1 receptor; serotonin uptake inhibitor; pregabalin; nicotinamide; interleukin 23; angiopoietin 1; infliximab; bullous skin disease; phototherapy; dronabinol; calcipotriol; immune checkpoint inhibitor; tocilizumab; nivolumab; stevens-johnson syndrome; hla drb1 antigen; dermatologic adverse events; lichenoid; humans; human; article; immune checkpoint inhibitors; immune-related adverse events; cutaneous adverse events; omalizumab; bullous pemphigoid; secukinumab; dupilumab; risankizumab; guselkumab; acitretin; cxcl10 gene; cxcl11 gene; skin hypersensitivity |
| Journal Title: | Journal of Allergy and Clinical Immunology: In Practice |
| Volume: | 12 |
| Issue: | 5 |
| ISSN: | 2213-2198 |
| Publisher: | Elsevier B.V. |
| Date Published: | 2024-04-30 |
| Start Page: | 1132 |
| End Page: | 1136 |
| Language: | English |
| DOI: | 10.1016/j.jaip.2024.03.034 |
| PUBMED: | 38548170 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work